BR96 sFv-PE40, a recombinant DNA-derived fusion protein composed of the heavy-and light-chain variable region domains of the monoclonal antibody BR96 and the translocation and catalytic domains of Pseudomonas exotoxin A, is being developed for the treatment of solid tumors expressing cell surface Lewis y -related antigens. Single-and repeat-dose intravenous toxicity studies in rats and dogs and a comparative ex vivo tissue-binding study with rat, dog, and human tissues were conducted to assess the toxicity of BR96 sFv-PE40 and to estimate a safe starting dose in humans. Additional studies were performed to investigate the prevention of pulmonary vascular-leak syndrome, the dose-limiting toxicity of BR96 sFv-PE40 in rats, and the immunogenicity of BR96 sFv-PE40.
INTRODUCTION
BR96 sFv-PE40 is a recombinant single-chain immunotoxin fusion protein consisting of the linked heavy-and light-chain variable regions of the murine monoclonal antibody BR96 (mBR96) fused to a binding-defective form of Pseudomonas exotoxin A (PE40) (2) . BR96 is an internalizing antibody that binds to the Lewisy (Ley) carbohydrate antigen that is expressed at high levels on the cell surface of many human tumors (6) and to a lesser extent by some normal cells, including epithelial cells of the gastrointestinal tract. Upon internalization of BR96 sFv-PE40 into endosomes, the PE40 is proteolytically cleaved and translocated to the ribosome where there is subsequent inhibition of protein synthesis by ADP-ribosylating elongation factor 2. Thus, the BR96 antibody directs the cytotoxic effect of the toxin to cells that express Ley-related antigens. In vivo studies in mice, which do not express Ley-related antigens on normal tissue, and rats, which do express Ley-related antigens on normal tissue, have demonstrated that BR96 sFv-PE40 is a potent antitumor agent at doses ranging from 0.05 to 0.1 mg/kg (10, Early exploratory studies in rodents indicated that the rat, but not the mouse, developed a pulmonary vascularleak syndrome (VLS) following toxic doses of BR96 sFv-PE40 (13) . This finding was of interest because other immunotoxins tested in humans, including those containing ricin A or Pseudomonas exotoxin A as the toxin, have been associated with dose-limiting VLS (1, 3-5, 8, 14, 15 ). In addition, the rat, unlike the mouse but similar to humans, expresses Ley in its gastrointestinal tract. Thus, the rat was chosen as the rodent species to utilize in the preclinical safety evaluation.
In preclinical dog studies and phase I human trials with the chimeric monoclonal BR96 antibody conjugated to doxorubicin (chBR96-Dox), the major dose-limiting effect was acute gastrointestinal toxicity characterized by repeated episodes of emesis with or without blood. In dogs, significant acute toxicity was observed after single doses of ?400 mg/m2 of the antibody (chBR96) alone. In these dogs, the upper small intestine (particularly the duodenum) appears to be most severely affected, with a loss of the epithelial component of the mucosa, congestion, edema, and hemorrhage. In dogs, investigative studies of the naked antibody have shown that the acute enteropathy is dependent on the level of expression of Leyrelated antigens by mucosal epithelial cells in the gut. A human volunteer given 550 mg/m'-of the naked chimeric antibody developed acute gastrointestinal toxicity with repeated episodes of hematemesis and acute gastritis and duodenitis. In addition, during the preclinical testing of chBR96-Dox or the naked chimeric antibody, the acute gastroenteropathy did not occur in rats or monkeys despite the administration of very large doses >2,000 mg/ m'-. For this reason, the dog was selected as the nonrodent species for preclinical safety testing of BR96 sFv-PE40.
To assess the toxicity of BR96 sFv-PE40, single-and repeat-dose intravenous studies in rats and dogs and a comparative ex vivo tissue-binding study with rat, dog, and human tissues were conducted. Additional studies were performed to investigate the prevention of pulmonary VLS, the dose-limiting toxicity of BR96 sFv-PE40 in rats, and the immunogenicity of BR96 sFv-PE40.
RAT STUDIES

Single-Dose Intravenous Study
Single doses of 0, 1.8, 3.6, or 7.2 Mg/M2 (equivalent to 0, 0.3, 0.6, or 1.2 mg/kg, respectively) BR96 sFv-PE40 were given intravenously to groups consisting of 10 male and 10 female Sprague-Dawley rats. Scheduled necropsies were conducted on days 3 and 31 to assess acute toxicity, and reversibility and delayed toxicity, respectively. Complete histopathologic examinations were conducted.
Exposure (as determined by maximum concentration
[CMAX] and area under the curve [AUC]) of rats following intravenous administration of BR96 sFv-PE40 was proportional to dose. Mean plasma concentrations declined by more than 95% within 24 hr after treatment, and overall mean half-life was 2.7 hr. Antibodies to BR96 sFv-PE40 were generally detected by day 15 in the lowand intermediate-dose groups, indicating that BR96 sFv-PE40 is immunogenic following a single dose in rats.
All high-dose rats were found dead on day 3, with rough haircoats and soiling noted in several rats prior to death. Transient soiling, primarily around the nose, was also noted in 5 low-dose and Based on the results of this study, the dose-limiting toxicity of BR96 sFv-PE40 was pulmonary VLS, with deaths occurring within 48 hr after single doses of 7.2 mg/m2. A single dose of 1.8 mg/m2 (0.3 mg/kg) resulted in generally minimal toxicity and was well tolerated. Single doses of up to 3.6 mg/m2 were nonlethal, and all toxicities at these doses were readily reversible over the 1-mo dose-free observation period. However, BR96 sFv-PE40 was immunogenic in rats, and all rats had antiimmunotoxin antibodies by the end of the dose-free observation period.
Repeat-Dose Intravenous Studies
In a repeat-dose intravenous range-finding study in rats, the toxicity of a total of 5 doses at a fixed dose level was investigated to determine if the dose-free interval between different treatment regimens had any impact on the toxicity of BR96 sFv-PE40. Doses of 1.5 or 2.1 mg/ m2 (0.25 or 0.35 mg/kg) were given every second, third, or fourth day for a total of 5 doses (q2dX5, q3d X 5, and q4dX5, respectively), and the results were compared with those for rats given doses of 0.75 mg/m2 (0.125 mg/kg) or 1.5 mg/m2 daily for 5 days (qdX5). When given daily, a dose of 1.5 mg/m2 was lethal to 6 of 10 rats within 1-4 days after completion of treatment, with deaths attributed to pulmonary VLS. Deaths did not occur with any of the other treatment schedules. Based on the transient body weight effects and the hematology and serum chemistry changes, the q2dX5 was more toxic than the q3dX5 or q4d X 5 schedules, which were similar. However, because anti-immunotoxin antibodies were detected in some rats as early as 6 days after the first dose, a q2d X 5 schedule was selected for the definitive toxicity study to minimize the potential for reduced exposure as a result of antibody formation.
In the definitive 2-wk intermittent-dose toxicity study, groups consisting of 10 Sprague-Dawley rats each were given intravenous injections of 0, 0.75, 1.5, or 3.0 mg/ m2 BR96 sFv-PE40 (equivalent to 0, 0.125, 0.25, or 0.50 mg/kg, respectively) once every 2 days for a total of 5 doses (q2dX5) to achieve cumulative doses of 3.8, 7.5, or 15 mg/m2. Scheduled necropsies were conducted on 5 surviving rats per sex in each group at 3 and 34 days after completion of treatment to assess acute toxicity, and reversibility and delayed toxicity, respectively. Complete histopathologic examinations were conducted on all rats. Exposure of rats (as determined by CMAX and AUC) was linearly related to or proportional to the intravenous dose on days I and 9. Compared with the first dose, CMAX after the last dose (day 9) was decreased at all dose levels. Furthermore, overall mean AUC values of intermediateand high-dose groups were lower after the fifth dose than after the first dose. The onset of the antibody response to the immunotoxin was generally dose related, and positive antibody titers were detected in all dose groups by day 19. None of the low-dose rats had a positive antibody response prior to the fifth dose, and AUCs in this group were similar for the first and fifth doses. Nineteen percent and 29% of the rats in the intermediate-and high-dose groups, respectively, had positive antibody responses prior to the fifth dose; however, the magnitude of these titers was relatively low, and all rats had significant exposure to the immunotoxin after the fifth dose, albeit AUCs were lower than those for the first dose in both groups.
In the high-dose group, 6 male and 2 female rats died or were euthanatized in moribund condition after administration of the fourth or fifth dose. High-dose rats exhibited clinical signs of toxicity, including dehydration, decreased activity, and diminished righting reflex, by the fourth dose. Decreased body weights (high dose) and food intakes (intermediate and high doses) occurred during the dosing period. Transient decreases in body weight gains were noted in the low-dose female rats 6 days after completion of treatment. Recovery of appetite and body weight gains were noted in all groups during the dosefree observation period.
Drug-related changes in clinicopathologic parameters were observed primarily on days [11] [12] and 19. Hematologic changes consisted of increased total leukocytes and platelets in high-dose rats, decreased absolute lymphocyte counts at all dose levels, and increased fibrinogen in low-and intermediate-dose rats. Drug-related changes in serum chemistry included increases in aspartate aminotransferase and decreases in total protein at all dose levels and increases in glucose (secondary to stress) and cholesterol in high-dose rats. Urinary white blood cells and/or urinary epithelial cells were increased at all dose levels.
Drug-related gross findings consisted of pulmonary congestion and edema in high-dose rats. Histopathologic changes in high-dose rats at the end of treatment consisted of pulmonary edema, congestion, and macrophage infiltration in rats that died early, focal cerebral edema with petechiae and necrosis, and interstitial inflammation in the heart, all considered to be secondary to VLS. Other findings included minimal single-cell necrosis of pancreatic acinar cells in all dose groups, degeneration and single-cell necrosis of renal cortical tubules at the intermediate and high doses, and lymphoid necrosis secondary to stress at the high dose. After the 1-mo dose-free observation period, the only lesions observed were minimal residual changes in the cerebrum of 1 high-dose rat.
In summary, when administered intravenously on a q2dX5 schedule, BR96 sFv-PE40 induced a dose-related VLS with associated lesions in the lungs, brain, and heart and pancreatic and renal single-cell necrosis. BR96 sFv-PE40 was immunogenic in rats, but with this schedule, all doses resulted in significant exposure. Doses of 0.75 and 1.5 mglm'-(cumulative doses of 3.8 and 7.5 mg/m'-) were generally well tolerated clinically, with only transient and relatively minor changes in serum chemistry and urinalysis. No overt toxicity and no evidence of drugrelated toxicity were observed at the end of the dose-free observation period. The high dose (3 mglm-'/dose and 15 Abbreviation: NE = not evaluated.° BR96 sFv-PE40 (2 mg/kg) was administered iv either alone or 2 hr after the last pretreatment dose of diphenhydramine ( 1 mg/kg, ip, daily for 2 days), CsA ( 100 mg/kg, sc, daily for 3 days), DSG ( 10 mg/kg, ip, daily for 3 days), Dex ( DS (100 ip, daily for 3 days), indomethacin (15-30 mg/kg, sc, 2 hr predose), or DS ( 100 mg/kg, ip, daily for 3 days), or 3 hr after CVF (100 U/kg, iv). Animals were either euthanatized at 24 hr to measure thoracic fluid or observed for mortality. ' ' Number alive/total number. ' Fluid collected 24 hr after BR96 sFv-PE40 administration. mg/m2 cumulative) was lethal during the treatment period because of VLS, with pulmonary, cerebral, and myocardial involvement. Other drug-related findings noted only at the end of treatment included single-cell necrosis of the pancreas (minimal at all doses) and renal tubules (intermediate and high doses).
Prevention of VLS
One of the dose-limiting toxicities seen with immunotoxins in clinical settings has been VLS (1, 3-5, 8, 14, 15) , characterized by peripheral edema, hypoalbuminemia, increased hematocrit, weight gain, and hypotension. Rats given a single dose of BR96 sFv-PE40 respond with dose-dependent VLS similar to that seen in humans (13) . The VLS response is seen as an accumulation of thoracic fluid and pulmonary edema with a concomitant increase in hematocrit and body weight and a decrease in serum albumin levels. Deaths from acute VLS occur 48-72 hr after administration of BR96 sFv-PE40 primarily due to massive fluid accumulation in the lungs and thoracic cavity.
Because VLS has been dose limiting with other immunotoxins in the clinic setting, studies were undertaken to assess whether BR96 sFv-PE40-induced VLS in rats could be prevented by prophylactic drug treatment. Utilizing this model, different anti-inflammatory agents, including dexamethasone (a corticosteroid that inhibits the release of arachidonic acid from membrane phospholipids), indomethacin (a nonsteroidal anti-inflammatory agent and cyclo-oxygenase inhibitor), and immunosuppressive agents, including deoxyspergualin and cyclosporin A, were examined for their ability to prevent VLS. Diphenhydramine (an antihistamine), cobra venom factor (a serum complement depleter), and dextran sulfate (a plasma volume expander) were also evaluated. Table I summarizes the results of several different studies in which rats were left untreated or were pretreated with these drugs prior to a 12 mg/m2 intravenous dose of BR96 sFv-PE40 (12, 13, unpublished data). Of the drugs tested, only dexamethasone and indomethacin had any beneficial effect on preventing VLS. No deaths and/or evidence of hydrothorax were observed in rats pretreated with dexamethasone or indomethacin. Thus, BR96 sFv-PE40-induced VLS could be prevented in rats with prophylactic anti-inflammatory agents.
DOG STUDIES
Single-and repeat-dose toxicity studies were also conducted in beagle dogs. In these studies, individual dogs were prescreened to determine the level of LeY expression based on samples obtained from buccal mucosa. At least 1 high Ley-expresser dog of each sex was included in each BR96 sFv-PE40 treatment group. These dogs were euthanatized at the early necropsy in both studies. Based on the findings in these studies, an additional repeat-dose study was conducted to determine a no-effect dose for pancreatic toxicity and to assess whether the histopathologic target-organ toxicity (pancreas) could be monitored by clinicopathologic testing. Because the target-organ toxicity was believed to be a consequence of the immunotoxin binding to Ley-expressing cells, the latter studies used predominantly high Ley-expressing dogs. An additional study was conducted in dogs to determine if the immunosuppressant CTLA4Ig could be used to prevent the antibody response to BR96 sFv-PE40 following repeat dosing.
Single-Dose Intravenous Study
In the single-dose toxicity study, intravenous injections of 0, 2.5, 6, and 15 mg/m2 (equivalent to 0, 0.12, 0.3, and 0.75 mg/kg, respectively) BR96 sFv-PE40 were given to groups consisting of 3 male and 3 female beagle dogs. Scheduled necropsies were conducted on day 3 (2 dogs per sex: 1 high and I low Ley expresser when possible) and day 30 (1 dog per sex) to assess acute toxicity, and reversibility and delayed toxicity, respectively. Complete histopathologic examinations were conducted on all dogs.
CMAX and AUC were dose proportional. Mean plasma concentrations declined by >99% within 24 hr after dosing, and overall mean half-life was 4.0 hr. No differences in toxicokinetic profiles were apparent between male and female or lowand high-Ley-expressing dogs. This finding is in contrast to results reported for the full antibody BR96 or the antibody-doxorubicin conjugate, which showed that high-Ley-expressing dogs had a significantly faster clearance of the intact antibody BR96 or the chBR96-Dox than did low-Ley expressing dogs.
One male high Ley expresser and I female low Ley expresser treated with 15 mg/m2 either died or was euthanatized in moribund condition on day 3. Bloody diarrhea and/or bloody emesis were observed prior to death or moribund euthanasia. Emesis was noted 6-48 hr after treatment, and transient hind-limb lameness/weakness was noted on day 2 in the intermediateand high-dose groups. This transient lameness/weakness in dogs was also noted with chBR96-Dox, although no neuromuscular lesions were detected with either drug. This clinical finding generally resolved within 24 hr, and with chBR96-Dox, similar findings have not been observed in humans. Additional clinical findings included transient minimal to moderate body weight loss and moderate to marked decreases in food consumption during the first week after treatment. Anti-immunotoxin antibodies were observed in all dogs; the response was dose dependent and was observed as early as 9 days after treatment.
Clinicopathologic changes induced by BR96 sFv-PE40 included generally transient and dose-related increases in leukocytes (neutrophils), fibrinogen, alanine and aspartate aminotransferases, alkaline phosphatase, and amylase (the latter only in the moribund high-dose male) and decreases in albumin. Changes in fibrinogen, aminotransferase, and albumin were slightly prolonged in high-dose dogs during the dose-free observation period. Additional late changes included decreases in lipase, cholesterol, triglycerides, and total protein, primarily in high-dose dogs. Decreases in sodium chloride and/or potassium levels were also noted, primarily in high-dose males on day 3, and increased casts in the urine of intermediate-and highdose dogs on day 3 were considered drug related. Decreased liver weight was observed in one high-dose male at the end of the dose-free observation period.
Histopathologically, the immunotoxin induced generally doseand/or Ley-related necrosis or single-cell necrosis that was most severe in the pancreas (Fig. 1 ), salivary gland, esophagus, and stomach. Necrosis was sometimes accompanied by hemorrhage and/or acute inflammation. Pancreatic and gastric hemorrhagic necrosis was considered the cause of death or moribund condition of the 2 high-dose dogs on day 3. Except for pancreatic atrophy at the high dose, the majority of changes were largely reversed by day 30. The severity of histopathologic changes in Ley-expressing tissues did not always correlate with the Ley expression based on evaluation of buccal epithelial cells. However, tissues that have been shown to be routinely negative or equivocal for BR96tissue binding typically had no drug-related histopathologic changes even at the high dose.
In summary, single doses of BR96 sFv-PE40 were associated with dose-dependent, transient inappetence and body weight loss. Gross and histopathologic findings were generally confined to Ley-expressing tissues, particularly the pancreas, stomach, esophagus, and salivary glands. The major dose-limiting toxicities were pancreatic acinar necrosis and to a lesser extent gastric mucosal necrosis and hemorrhage. Except for the pancreatic atrophy at the high dose, all acute changes resolved during the 30-day dose-free observation period.
Repeat-Dose Intravenous Studies
In the 2-wk intermittent-dose toxicity study, groups consisting of 3 male and 3 female beagle dogs were given intravenous injections of 0, 1.2, 2.4, or 4.8 mg/m2 (equivalent to 0, 0.06, 0.12, or 0.24 mg/kg, respectively) BR96 sFv-PE40 once every 3 days for 5 doses {q3dX5), achieving cumulative doses of 0, 6, 12, and 24 mglm'-, respectively. Scheduled necropsies were conducted 3 days after completion of treatment (day 15, 2 dogs per sex: 1 high and 1 low Ley expresser when possible) and 28 days after completion of treatment (day 42, 1 dog per sex) to assess acute toxicity, and reversibility and delayed toxicity, respectively. Histopathologic examinations were conducted on complete tissue sets from all dogs.
Systemic exposures following administration of the Remaining parenchyma consists primarily of small ducts, condensed stroma, a few cells considered to be regenerating acinar cells, and rare acini with more typical appearance and often with several necrotic acinar cells. Bar = 25 ~tm. first (day 1) and third (day 7) doses were dose proportional. However, after the fifth dose (day 13), CMAX and AUC values were not dose proportional and were markedly lower. The more rapid clearance of immunotoxin after the fifth dose was attributed to development of antidrug antibodies that occurred as early as 8-12 days after the first dose.
No deaths occurred at any dose. During or after the first 3 doses, emesis (all doses) and transient weakness/ lameness of the hind limbs (intermediate and high doses) were observed. Acute hypersensitivity reactions were first noted after the third dose. These reactions consisting of emesis/retching, pale mucous membranes, flushed extremities, bloody stool, vocalization, tremors, and markedly decreased activity/prostration occurred in all but 1 low-dose dog. The dogs recovered within 15 min to 1 hr. Within individual dogs, subsequent hypersensitivity reactions, if any, were not as severe as the first reaction.
These reactions correlated with high titers of anti-immunotoxin antibodies. Additional findings included irritation at injection sites, dose-dependent minimal to mild body weight loss, and transient but sometimes marked inappetence. There was no apparent correlation between Ley expression and the observed clinical signs.
Clinicopathologic changes noted at the end of treatment included transient increases in fibrinogen and aminotransferases and decreases in protein and/or albumin at all doses and dose-dependent increases in leukocyte count (neutrophils) and cholesterol at doses of 2.4 and 4.8 Mg/M2. A delayed decrease in lipase occurred at the high dose.
Drug-related gross pathologic findings noted at the end of treatment included atrophy of the pancreas, primarily in high-dose dogs, and atrophy of the thymus in highdose females. At the end of the 28-day dose-free observation period, atrophy of the pancreas and thymus was noted only in the high-dose male dog. The major drugrelated histopathologic findings were limited to known Ley-expressing tissues. In dogs euthanatized at the end of treatment, histopathologic findings at the low dose were limited to single-cell necrosis, minimal regeneration of acinar cells, lymphocytic inflammation and mild atrophy of the pancreas, and minimal to mild atrophy of the salivary gland with lymphocytic infiltration. Generally, similar findings were observed in intermediate-dose dogs; however, slightly greater atrophy and single-cell necrosis of the exocrine pancreas were observed along with minimal to moderate atrophy of submucosal glands in the esophagus. At these doses, no drug-related findings were detected in dogs after a 1-mo dose-free observation period except for minimal atrophic changes in the salivary gland and submucosal esophageal glands at 2.4 Mg/M2. At the end of treatment, drug-related histopathologic findings in Le>'-expressing tissues of high-dose dogs were generally more severe. In addition to changes in the pancreas, salivary gland, and esophageal submucosal glands, minimal fundic glandular epithelial vacuolation in the stomach was observed. Additional indirect findings in these dogs included focal inflammatory changes in the lungs (related to aspiration of vomitus at the end of treatment), thymic involution, and bone-marrow depletion (all considered secondary to stress) and atrophy of the male reproductive organs after the 1-mo dose-free observation period.
In summary, with a q3dX5 dosing regimen, dogs developed high titers of anti-BR96 sFv-PE40 as early as 8-12 days after the first dose. The presence of these antiimmunotoxin antibodies significantly increased elimination of BR96 sFv-PE40 and was associated with acute hypersensitivity responses as early as the third dose. BR96 sFv-PE40 induced the most consistent changes in tissues known to express Ley antigens, including pancreas, esophagus, stomach, and salivary glands. The low dose (1.2 Mg/M2/dose, 6 mg/m2 cumulative) was generally well tolerated, resulting in mild, transient clinicopathologic changes and mild pancreatic and salivary gland atrophy at the end of treatment and no drug-related effects after a 28-day dose-free observation period. Slightly greater toxicity, as evidenced by transient effects on body weight, food intake, and clinicopathologic parameters and moderate pancreatic atrophy or mild pancreatic single-cell necrosis at the end of treatment, was observed at the intermediate dose (2.4 Mg/M2/dose, 12 mg/m2 cumulative), but all toxicities were resolved by the end of the dose-free observation period. At the high dose (4.8 mg/m2/dose, 24 mg/m2 cumulative), a broader spectrum of toxicity was observed, which included generally greater toxicity to Ley-expressing tissues and indirect involvement of other non-LeY-expressing tissues, including the lungs, liver, bone marrow, and reproductive organs of one high-dose male. Pancreatic atrophy was still evident in this high-dose male at the end of the 1mo dose-free observation period.
An additional repeat-dose (q3dX5) toxicity study was conducted in high-Ley-expressing dogs to determine a noeffect dose with regard to morphologic changes in the pancreas. Based on the interest in the identification of a clinically useful test to monitor BR96 sFv-PE40-induced effects on the pancreas, pancreatic function was also monitored by assessment of trypsinlike immunoreactivity (TLI) in addition to serum amylase and lipase levels. TLI, which measures the blood level of trypsinlike proteins, is believed to reflect the overall pancreatic mass and may be significantly decreased in cases of pancreatic insufficiency (9, 16, 17) . In addition, TLI has been reported to increase in cases of acute pancreatitis or necrosis (7, 9) . Doses of 0.024, 0.12, and 0.6 mg/m2 were given to groups of 4 dogs, 1 dose every 3 days for 5 doses (0.12, 0.6, and 3.0 mg/m'cumulative). The dogs were euthanatized and necropsied 2 days after the last dose. Serum amylase, lipase, and TLI were determined prior to euthanasia. No pancreatic toxicity was observed at the low dose, but minimal and mild single-cell necrosis of pancreatic acinar cells was observed at the intermediate and high doses, respectively. Pancreatic toxicity was most evident in 1 high-dose dog that had significantly decreased TLI, moderate single-cell necrosis of acinar cells, and atrophy 2 days after completion of treatment. This dog had not developed a significant antidrug antibody response during the treatment period, suggesting that more severe pancreatic toxicity may have been due to greater BR96 sFv-PE40 exposure. No antidrug antibody response occurred at the low or intermediate doses. Overall, the results of this study indicate that significant pancreatic toxicity was not produced in dogs given <0.6 mg/m'-following a q3dX5 treatment regimen and suggest that TLI may be clinically useful to monitor pancreatic effects induced by BR96 sFv-PE40.
PREVENTION OF IMMUNOGENICITY BY COADMINISTRATION
OF AN IMMUNOSUPPRESSANT BR96 sFv-PE40 was immunogenic in all species tested. The presence of anti-BR96 sFv-PE40 antibodies in the serum increases the clearance of the drug, reducing the exposure to the drug. In addition, a significant antibody response to BR96 sFv-PE40 can result in an acute hypersensitivity reaction during or within minutes following subsequent doses. Treatment with an immunosuppressant may prevent or reduce the generation of an antibody response to BR96 sFv-PE40 and thus allow for a longer treatment period with concomitant greater exposure and reduced antibody-mediated toxicity.
A study was performed in dogs to determine if the coadministration of the immunosuppressant CTLA4Ig (an inhibitor of T-cell activation) with BR96 sFv-PE40 could be used to inhibit or delay the onset of an antibody response to BR96 sFv-PE40 when given repeatedly (q3dX5) ( 11 ) . The impact of CTLA4Ig cotherapy on the induction of antibody-mediated hypersensitivity reactions and the exposure (clearance) of BR96 sFv-PE40 following repeat-doses was also evaluated. Two groups of 4 beagle dogs each were given 2.4 mg/m2 BR96 sFv-PE40 intravenously using a schedule of q3dX5. One group received BR96 sFv-PE40 alone and the other group received 10 mg/kg CTLA4Ig intravenously on the same schedule, including at challenge on day 34. Following the fourth dose, 3 of 4 dogs treated with BR96 sFv-PE40 alone had hypersensitivity reactions within 15 min of injection. In contrast, none of the dogs treated with BR96 sFv-PE40 and CTLA4Ig displayed any signs of a hypersensitivity reaction through all 5 doses of BR96 sFv-PE40. All dogs treated with only BR96 sFv-PE40 developed a positive anti-BR96 sFv-PE40 antibody response by day 10 or 13 prior to the end of the q3dX5 dosing regimen (Fig. 2 ). CTLA4Ig treatment generally delayed the onset of the response until after the q3d X 5 dosing regimen was completed (mean titer suppressed ~90%). By day 34, CTLA4Ig suppressed the mean anti-BR96 sFv-PE40 antibody response by 83% when compared with animals treated with BR96 sFv-PE40 alone. The rapid elimination of BR96 sFv-PE40 on day 13 in the dogs treated with BR96 sFv-PE40 alone, which was mediated by the formation of anti-BR96 sFv-PE40 antibodies, was decreased or prevented by treatment with CTLA4Ig. However, CTLA4Ig did not completely prevent the anti-BR96 sFv-PE40 antibody-mediated elimination of BR96 sFv-PE40 following the challenge dose on day 34, although this effect was greatly reduced compared with the effect in dogs treated with BR96 sFv-PE40 alone. In summary, concomitant treatment with CTLA4Ig significantly reduced and/or delayed the anti-BR96 sFv-PE40 antibody responses, allowing for longer duration of mg/kg CTLA4Ig on the same days of BR96 sFv-PE40 treatment, including at challenge on day 34. Serum levels of BR96 sFv-PE40 and antibody titers to BR96 sFv-PE40 were assessed. treatment with greater exposure and reduced antibodymediated toxicities.
COMPARATIVE TISSUE BINDING STUDY WITH RAT, DOG, AND HUMAN TISSUE
An ex vivo comparative tissue-binding study was conducted to evaluate by immunohistochemistry the staining of BR96 sFv-PE40 in selected tissues of rats, dogs, and humans (unpublished data). The intent of this study was to demonstrate whether the ex vivo tissue staining with BR96 sFv-PE40 of rat and dog tissues, species in which the toxicity of BR96 sFv-PE40 was evaluated in vivo, was similar to that observed in human tissues.
In all species tested, the majority of tissues that demonstrated significant staining with mBR96 also demonstrated the greatest degree of staining with BR96 sFv-PE40. Tissues that stained with both mBR96 (Ley-expressing tissue) and BR96 sFv-PE40 in at least 1 test species were adrenal gland, gastrointestinal tract, liver, lymph node, kidney, pancreas, parathyroid, pituitary, prostate, salivary gland, skin, spinal cord, spleen, and urinary tract. Unexpected equivocal to slight or diffuse staining with BR96 sFv-PE40 was observed in several non-Ley-expressing tissues, including bone marrow, central nervous system, heart, lung, ovary, skeletal muscle, testes, thyroid gland, thymus, and uterus. This diffuse staining was not observed at a lower, more pharmacologically relevant, concentration of BR96 sFv-PE40.
Overall, the results of this study suggest that the potential for binding to non-Ley-expressing tissues presents considerably less risk to human patients than the binding to Ley-expressing tissues. Because both the rat and dog had BR96 sFv-PE40 staining patterns similar to those seen in humans, these data support the use of rats and dogs as relevant species to examine the preclinical toxicity of BR96 sFv-PE40.
SUMMARY
Single-and repeat-dose intravenous toxicity studies in rats and dogs and an ex vivo tissue-binding study of BR96 sFv-PE40 have been conducted. The findings observed in the single-and repeat-dose rat studies indicate that rats tolerate higher doses when administered as a cumulative dose rather than as a single dose and that the primary dose-limiting toxicity is VLS, regardless of the treatment regimen. However, VLS could be prevented in rats by prophylactic treatment with anti-inflammatory agents. In single-dose rat studies, the VLS appeared to be primarily confined to the lungs; however, with a repeat-dose regimen (q2dx5) other organs were also involved. Single doses of 1.8 mg/m~ and a cumulative dose of 3.8 mglm'-(0.75 mg/m'-, q2dX5) were generally well tolerated in rats. The toxicity profile of BR96 sFv-PE40 in dogs following single or repeat doses was generally similar. Dogs survived greater cumulative doses over a 2-wk period compared with a single administration; however, BR96 sFv-PE40 was immunogenic in dogs, and in the presence of an antidrug antibody response, BR96 sFv-PE40 was cleared much more rapidly, which resulted in reduced exposures in the repeat-dose studies. In addition, the presence of a high antidrug antibody titer in dogs was associated with an acute hypersensitivity response during or shortly after BR96 sFv-PE40 treatment. However, the generation of an antibody response to BR96 sFv-PE40 could be significantly reduced and/or delayed by concomitant treatment with the immunosuppressant CTLA4Ig. The major toxicities observed in dogs were predominantly restricted to Le}'-expressing tissues, including the pancreas, salivary glands, submucosal glands in the esophagus, and mucosa of the stomach. Pancreatic toxicity and to a lesser extent acute hemorrhagic gastritis appeared to be the major dose-limiting toxicities. After a 1-mo dose-free observation period, no residual pancreatic toxicity was observed in dogs given single doses up to 6.0 mg/m2 or 5 doses of 2.4 mg/m2 (12 mg/m'-cumulative). The TLI test was useful for monitoring changes in pancreatic function after BR96 sFv-PE40 administration. Based on results with the q3dX5 dose regimen in high-LeY-expressing dogs, no significant pancreatic toxicity was observed at doses <0.6 mg/m2. Because both the rat and the dog had BR96 sFv-PE40 staining patterns similar to that of humans in the comparative tissue binding study, these data support the use of rats and dogs as relevant species to examine the preclinical toxicity of BR96 sFv-PE40.
